Literature DB >> 2957106

Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.

M L Zanette, U Tirelli, R Sorio, D Zadro, F Figoli, S Monfardini, M D'Incalci.   

Abstract

The pharmacokinetics of 7-con-O-methylnogarol were investigated by HPLC assay with fluorometric detection in nine cancer patients with normal hepatic and renal function, after a 2-h infusion of 160 or 200 mg/m2. The drug disappeared from plasma biexponentially with a mean elimination half-life of 38 +/- 3 h; the mean apparent volume of distribution and the plasma clearance were 805 +/- 91 1/m2 and 14 +/- 2 1/h per m2. Within 48 h of administration, urinary excretion of the drug and its metabolite 7-con-O-methyl-N-demethylnogarol accounted for 2%-15% and 0.1%-6% of the dose, respectively. Neither 7-con-O-methylnogarol nor its N-demethyl derivative was conjugated with glucuronic acid or sulfate in detectable amounts.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957106     DOI: 10.1007/bf00252962

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  NL-FIT: a microcomputer program for non-linear fitting.

Authors:  G S Landriani; V Guardabasso; M Rocchetti
Journal:  Comput Programs Biomed       Date:  1983 Feb-Apr

2.  Rapid high-performance liquid chromatographic assay for the anthracyclines daunorubicin and 7-con-O-methylnogarol in plasma.

Authors:  J E Brown; P A Wilkinson; J R Brown
Journal:  J Chromatogr       Date:  1981-12-11

3.  Comparative biological and biochemical effects of nogalamycin and its analogs on L1210 leukemia.

Authors:  L H Li; S L Kuentzel; L L Murch; L M Pschigoda; W C Krueger
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

4.  Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent.

Authors:  J P McGovren; G L Neil; R H Denlinger; T L Hall; S L Crampton; J A Swenberg
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

5.  The disposition of the new anthracycline antibiotic, menogarol, in mice.

Authors:  P Dodion; B K Chang; M J Egorin; E A Olman; K L Engisch; N R Bachur
Journal:  Drug Metab Dispos       Date:  1984 May-Jun       Impact factor: 3.922

6.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.

Authors:  J P McGovren
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

8.  Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.

Authors:  M J Egorin; D A Van Echo; M Y Whitacre; A Forrest; L M Sigman; K L Engisch; J Aisner
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

9.  Metabolism and disposition of menogaril (NSC 269148) in the rabbit.

Authors:  P Dodion; M J Egorin; K L Engisch; N R Bachur
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

10.  Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.

Authors:  G L Neil; S L Kuentzel; J P McGovren
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec
View more
  1 in total

1.  Human autopsy-tissue distribution of menogaril and its metabolites.

Authors:  D J Stewart; D Grewaal; R M Green; R Goel; N Mikhael; V A Montpetit; D Redmond; R Earhart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.